SAB BIOTHERAPEUTICS, INC. Earnings Per Share (Basic)
SAB BIOTHERAPEUTICS, INC. (SABS) reported Earnings Per Share (Basic) of -$0.28 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.28.
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.35.
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.06.
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was $0.50.
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was $0.22.
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$3.68.
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$7.64.
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$4.31.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.28 10-Q · filed 2026-08-06 | -$0.62 10-Q · filed 2026-08-06 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2026-03-31 | -$0.35 10-Q · filed 2026-05-12 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-12-31 | -$0.06 derived: net income ÷ weighted average shares · filed 2026-03-09 | $0.08 derived: net income ÷ weighted average shares · filed 2026-03-09 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.22 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $0.50 10-Q · filed 2025-11-14 | -$0.48 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.73 10-Q · filed 2025-11-14 | -$2.22 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-06-30 | -$1.09 10-Q · filed 2026-08-06 | -$1.65 10-Q · filed 2026-08-06 | -$2.87 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$3.99 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-03-31 | -$0.56 10-Q · filed 2026-05-12 | -$1.79 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$2.90 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$3.70 derived: net income ÷ weighted average shares · filed 2026-05-12 | ||||
| 2024-12-31 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-03-09 | -$2.34 derived: net income ÷ weighted average shares · filed 2026-03-09 | -$3.14 derived: net income ÷ weighted average shares · filed 2026-03-09 | -$3.68 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | -$1.12 10-Q · filed 2025-11-14 | -$1.91 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$2.45 10-Q · filed 2025-11-14 | -$5.28 derived: net income ÷ weighted average shares · filed 2025-11-14 | ||||
| 2024-06-30 | -$0.79 10-Q · filed 2025-08-07 | -$1.34 10-Q · filed 2025-08-07 | -$4.18 derived: net income ÷ weighted average shares · filed 2025-08-07 | -$5.29 derived: net income ÷ weighted average shares · filed 2025-08-07 | ||||
| 2024-03-31 | -$0.54 10-Q · filed 2025-05-09 | -$3.48 derived: net income ÷ weighted average shares · filed 2025-05-09 | -$4.66 derived: net income ÷ weighted average shares · filed 2025-05-09 | -$6.07 derived: net income ÷ weighted average shares · filed 2025-05-09 | ||||
| 2023-12-31 | -$3.38 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$4.66 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$6.13 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$7.64 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$0.97 10-Q · filed 2024-11-06 | -$0.10 10-Q · filed 2023-11-13 | -$2.33 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$3.79 10-Q · filed 2024-11-06 | -$0.38 10-Q · filed 2023-11-13 | $1.13 derived: net income ÷ weighted average shares · filed 2024-11-06 | ||
| 2023-06-30 | -$1.36 10-Q · filed 2024-08-08 | -$0.14 10-Q · filed 2023-08-21 | -$2.82 10-Q · filed 2024-08-08 | -$0.28 10-Q · filed 2023-08-21 | $0.65 derived: net income ÷ weighted average shares · filed 2024-08-08 | $1.99 derived: net income ÷ weighted average shares · filed 2024-08-08 | ||
| 2023-03-31 | -$1.46 10-Q · filed 2024-05-20 | -$0.15 10-Q · filed 2023-05-15 | $0.29 derived: net income ÷ weighted average shares · filed 2024-05-20 | $1.05 derived: net income ÷ weighted average shares · filed 2024-05-20 | $5.25 derived: net income ÷ weighted average shares · filed 2024-05-20 | |||
| 2022-12-31 | $0.07 derived: net income ÷ weighted average shares · filed 2024-03-29 | $0.44 derived: net income ÷ weighted average shares · filed 2024-03-29 | $2.30 derived: net income ÷ weighted average shares · filed 2024-03-29 | -$4.31 10-K · filed 2024-03-29 | -$0.43 10-K · filed 2023-04-14 | |||
| 2022-09-30 | -$0.16 10-Q · filed 2023-11-13 | -$0.28 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$0.25 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | -$0.11 10-Q · filed 2023-08-21 | -$0.09 10-Q · filed 2023-08-21 | ||||||
| 2022-03-31 | $0.02 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | -$0.63 10-K/A · filed 2023-04-28 | |||||||
| 2021-09-30 | -$0.16 10-Q · filed 2022-11-14 | -$0.27 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.22 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$0.11 10-Q · filed 2022-08-10 | -$0.06 10-Q · filed 2022-08-10 | ||||||
| 2021-03-31 | $0.05 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | $0.79 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |